Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule

Behavioural Pharmacology

Volumn 25, Issue 1, 2014, Pages 80-91

  Hillhouse, Todd M ^a   Porter, Joseph H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

antidepressants; depression; differential reinforcement of lowrate; glutamate; ketamine; MK 801; N methyl D aspartate; rat

Indexed keywords

DEXAMPHETAMINE; DIZOCILPINE; DRUG VEHICLE; FLUOXETINE; IMIPRAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIFFERENTIAL REINFORCEMENT OF LOW RATE TRAINING; DOSE RESPONSE; DRUG RECEPTOR BINDING; INSTRUMENTAL CONDITIONING; LATIN SQUARE DESIGN; MALE; NONHUMAN; OPERANT BEHAVIORAL TEST; RAT; REINFORCEMENT; RESPONSE TIME; TASK PERFORMANCE; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; CONDITIONING, OPERANT; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EXCITATORY AMINO ACID ANTAGONISTS; IMIPRAMINE; KETAMINE; MALE; N-METHYLASPARTATE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE;

EID: 84891847077     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000014     Document Type: Article

References (60)

1. Annhet R. M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139-145.
2. Altamura AC, Mauri CM, Ferrara A, Moro RA, D'Andrea G, Zamberlan F (1993). Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150:1731-1733. (Pubitemid 23325960)
3. Altamura C, Maes M, Dai J, Meltzer HY (1995). Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 5 (Suppl 1):71-75. (Pubitemid 26017262)
4. Ardayfio PA, Benvenga MJ, Chaney SF, Love PL, Catlow J, Swanson SP, et al. (2008). The 5-hydroxytryptamine2A receptor antagonist R-(+)-a-(2,3- dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J Pharmacol Exp Ther 327:891-897.
5. Auer DP, Pü tz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000). Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47:305-313.
6. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Peng-fei C, et al. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
7. Bechtholt-Gompf A, Smith K, John C, Kang H, Carlezon W Jr., Cohen B, et al. (2011). CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) 215:689-695.
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354. (Pubitemid 30109248)
9. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD, et al. (2011). Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 16:634-646.
10. Bespalov AY, van Gaalen MM, Sukhotina IA,Wicke K, Mezler M, Schoemaker H, et al. (2008). Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol 592:96-102.
11. Bhargava HN, Matwyshyn GA, Gudehithlu KP (1995). Effects of acute and chronic administration of dizocilpine on the pharmacological responses to U-50 488H and brain and spinal cord k-opioid receptors in the rat. Pharmacology 51:323-330.
12. Bresink I, Danysz W, Parsons CG, Mutschler E (1995). Different binding affinities of NMDA receptor channel blockers in various brain regions-indication of NMDA receptor heterogeneity. Neuropharmacology 34:533-540.
13. Burch RM (2012). A phase 2, randomized, double blind, single intravenous dose study of GLYX-13, an NMDA receptor glycine site functional partial agonist, in subjects with major depressive disorder with inadequate response to antidepressant medication. Presentation at the American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting; 2-6 December 2012; Hollywood, Florida.
14. Burgdorf J, Zhang X-l, Nicholson KL, Balster RL, Leander DJ, Stanton PK, et al. (2013). GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38:729-742.
15. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al. (2005). Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102:15653-15658. (Pubitemid 41528111)
16. Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, et al. (2007). Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol 581:107-128. (Pubitemid 46712031)
17. Engin E, Treit D, Dickson CT (2009). Anxiolytic-and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 161:359-369.
18. Fava M, Davidson KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
19. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM (2007). Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 61:162-166. (Pubitemid 46072777)
20. Hashimoto K, Sawa A, Iyo M (2007). Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310-1316. (Pubitemid 350060893)
21. Hirota K, Hashimoto Y, Lambert DG (2002). Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in Chinese Hamster ovary cells. Anesth Analg 95:1607-1610. (Pubitemid 35423948)
22. Institute of Laboratory Animal Resources (1996). Guide for the care and use of laboratory animals. 7th ed. Washington DC: Institute of Laboratory Animals Resources, Commission of Life Sciences, National Research Council.
23. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U (2012). Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21:169-184.
24. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH (1982). Increased serum glutamate in depressed patients. Arch Psychiatr Nervenk 232:299-304. (Pubitemid 13124834)
25. Koike H, Iijima M, Chaki S (2011). Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107-111.
26. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW (2000). Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 47:586-593. (Pubitemid 30169251)
27. Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
28. Li N, Liu R-J, Dwyer JM, Banasr M, Lee B, Son H, et al. (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754-761.
29. Lindholm JSO, Autio H, Vesa L, Antila H, Lindemann L, Hoener MC, et al. (2012). The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf +/-heterozygous null mice. Neuropharmacology 62:391-397.
30. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706. (Pubitemid 36263162)
31. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352. (Pubitemid 351146651)
32. McGuire PS, Seiden LS (1980). Differential effects of imipramine in rats as a function of DRL schedule value. Pharmacol Biochem Behav 13:691-694. (Pubitemid 11253892)
33. Mirza Y, Tang J, Russell A, Banerjee SP, Bhandari R, Ivey J, et al. (2004). Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 43:341-348. (Pubitemid 41615014)
34. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R (2006). Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30:1155-1158. (Pubitemid 43928219)
35. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927. (Pubitemid 27155025)
36. Molina-Hernández M, Tellez-Alcántara NP, Pé rez-Garc?́a J, Olivera-Lopez JI, Jaramillo MT (2006). Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 30:1129-1135. (Pubitemid 43928236)
37. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. (2012). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250-256.
38. Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S, et al. (1998a). Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88:768-774. (Pubitemid 28120212)
39. Nishimura M, Sato K, Okada T, Schloss P, Shimada S, Tohyama M (1998b). MK-801 blocks monoamine transporters expressed in HEK cells. FEBS Lett 423:376-380. (Pubitemid 28129369)
40. O'Donnell JM, Seiden LS (1982). Effects of monoamine oxidase inhibitors on performance during differential reinforcement of low response rate. Psychopharmacology (Berl) 78:214-218. (Pubitemid 13250845)
41. O'Donnell JM, Seiden LS (1983). Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs. J Pharmacol Exp Ther 224:80-88. (Pubitemid 13171034)
42. O'Donnell JM, Marek GJ, Seiden LS (2005). Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev 29:785-798. (Pubitemid 40755464)
43. Pá len?́c?ek T, Fujáková M, Brunovský M, Bal?́ková M, Horác? ek J, Gorman I, et al. (2011). Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics. Neuropsychobiology 63:202-218.
44. Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B (2010). Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 95:449-456.
45. Popik P, Kos T, Sowa-Kućma M, Nowak G (2008). Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 198:421-430.
46. Réus GZ, Stringari RB, Ribeiro KF, Ferraro AK, Vitto MF, Cesconetto P, et al. (2011). Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 221:166-171.
47. Richards JB, Sabol KE, Seiden LS (1993). DRL interresponse-time distributions: quantification by peak deviation analysis. J Exp Anal Behav 60:361-385.
48. Sakai R, Swanson GT, Shimamoto K, Green T, Contractor A, Ghetti A, et al. (2001). Pharmacological properties of the potent epileptogenic amino acid dysiherbaine, a novel glutamate receptor agonist isolated from the marine sponge Dysidea herbacea. J Pharmacol Exp Ther 296:650-658. (Pubitemid 32112496)
49. Schulberg HC, Katon W, Simon GE, Rush AJ (1998). Treating major depression in primary care practice: an update of the agency for health care policy and research practice guidelines. Arch Gen Psychiatry 55:1121-1127. (Pubitemid 28558285)
50. Seeman P, Ko F, Tallerico T (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877-883. (Pubitemid 43080122)
51. Smith DJ, Bouchal RL, DeSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, et al. (1987). Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 26:1253-1260. (Pubitemid 17154877)
52. Sokolowski JD, Seiden LS (1999). The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology (Berl) 147:153-161. (Pubitemid 30010562)
53. Sunal R, Gümü ş el B, Kayaalp SO (1994). Effect of changes in swimming area on results of 'behavioral despair test'. Pharmacol Biochem Behav 49:891-896.
54. Tikhonova IG, Baskin II, Palyulin VA, Zefirov NS (2004). 3D-model of the ion channel of NMDA receptor: qualitative and quantitative modeling of the blocker binding. Dokl Biochem Biophys 396:181-186. (Pubitemid 38918976)
55. Tizabi Y, Bhatti BH, Manaye KF, Das JR, Akinfiresoye L (2012). Antidepressantlike effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience 213:72-80.
56. Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, et al. (2011). Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the genome-based therapeutic drugs for depression (GENDEP) study. J Clin Psychiatry 72:1478-1484.
57. Vunck SA, Wiebelhaus JM, Arnt J, Porter JH (2011). Clozapine and N-methyl-Daspartate have positive modulatory actions on their respective discriminative stimulus properties in C57BL/6 mice. Eur J Pharmacol 650:579-585.
58. Wegener N, Nagel J, Gross R, Chambon C, Greco S, Pietraszek M, et al. (2011). Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour. Neurosci Lett 503:68-72.
59. Yang C, Li W-Y, Yu H-Y, Gao Z-Q, Liu X-L, Zhou Z-Q, et al. (2012). Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex. J Biomed Biotechnol 2012:6.
60. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 63:856-864. (Pubitemid 44188478)